WaterSep BioSeparations LLC (“WaterSep”) has been sold to Sartorius AG (“Sartorius”). Sartorius acquired WaterSep through its subgroup Sartorius Stedim Biotech. The parties agreed on a purchase price of approximately $27M plus an earn‑out component of up to $9M, depending on the achievement of defined sales revenue growth by 2023.

WaterSep develops, manufactures and markets hollow‑fiber membrane devices and pre-sterilized assemblies for upstream and downstream biopharmaceutical applications. The privately-owned company based in Marlborough, Massachusetts, USA, employs around 15 people and is expected to earn revenue of approximately $2.5M in 2020 at strong growth rates and a substantial double-digit EBITDA margin.

Sartorius operates in the life sciences and the biopharmaceutical industry. The transaction provides a complementary fit with Sartorius’ separation portfolio, adding innovative crossflow filtration units for easy-to-use bioprocessing devices. Technology is especially suited to gene and cell therapy applications, vaccine production and intensified bioprocessing.

EC M&A acted as M&A advisor to WaterSep on this transaction.

 

Bioprocessing, Cross border, Europe, North America, Sellside